Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.

IF 2.8 3区医学 Q2 ONCOLOGY

Clinical & Translational Oncology Pub Date : 2025-02-19 DOI:10.1007/s12094-025-03863-8

Mohammad Taghizadeh-Teymorloei, Vahid Jafarlou, Somaieh Matin, Mortaza Raeisi, Yousef Roosta, Sima Mansouri-Derakhshani, Abbas Ali Hosseinpour Feizi, Abbas Karimi

{"title":"Clinical implications of Alu-based cell-free DNA and serum onco-piRNA monitoring in colorectal cancer management.","authors":"Mohammad Taghizadeh-Teymorloei, Vahid Jafarlou, Somaieh Matin, Mortaza Raeisi, Yousef Roosta, Sima Mansouri-Derakhshani, Abbas Ali Hosseinpour Feizi, Abbas Karimi","doi":"10.1007/s12094-025-03863-8","DOIUrl":null,"url":null,"abstract":"Background: Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.Methods: We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.Results: Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.Conclusions: This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.","PeriodicalId":50685,"journal":{"name":"Clinical & Translational Oncology","volume":" ","pages":""},"PeriodicalIF":2.8000,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical & Translational Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12094-025-03863-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Colorectal cancer (CRC) remains a significant global health challenge, characterized by high morbidity and mortality rates. This study explores the potential of Alu-based cell-free DNA (cfDNA) and specific PIWI-interacting RNAs (piRNAs) as innovative biomarkers for monitoring treatment responses in CRC patients.

Methods: We analyzed plasma samples from 70 CRC patients, equally divided between those undergoing chemotherapy and surgical interventions.

Results: Our findings reveal that certain piRNAs, particularly piRNA-823, piRNA-54265, and piRNA-1245, exhibit significant prognostic value, with notable expression changes observed in the chemotherapy group compared to the surgery group. Furthermore, the levels of ALU-based cfDNA fragments showed a marked decrease post-chemotherapy, suggesting their utility in assessing therapeutic efficacy.

Conclusions: This research underscores the importance of integrating these molecular tools particularly piRNA-823 and ALU-based cfDNA into clinical practice, potentially enhancing the management strategies for CRC patients and improving their outcomes.

查看原文本刊更多论文

基于铝的无细胞DNA和血清onco-piRNA监测在结直肠癌治疗中的临床意义。

背景：结直肠癌（CRC）仍然是一个重大的全球健康挑战，其特点是高发病率和死亡率。本研究探讨了基于铝的无细胞DNA （cfDNA）和特异性piwi相互作用rna （piRNAs）作为监测结直肠癌患者治疗反应的创新生物标志物的潜力。方法：我们分析了70例结直肠癌患者的血浆样本，这些患者平均分为化疗组和手术组。结果：我们的研究结果显示，某些pirna，特别是piRNA-823， piRNA-54265和piRNA-1245具有显著的预后价值，化疗组与手术组相比表达显著变化。此外，基于alu的cfDNA片段的水平在化疗后显着降低，表明它们在评估治疗效果方面的效用。结论：本研究强调了将这些分子工具，特别是piRNA-823和基于alu的cfDNA整合到临床实践中的重要性，这可能会增强结直肠癌患者的管理策略并改善其预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical & Translational Oncology 医学-肿瘤学

CiteScore

6.20

自引率

2.90%

发文量

240

审稿时长

1 months

期刊介绍： Clinical and Translational Oncology is an international journal devoted to fostering interaction between experimental and clinical oncology. It covers all aspects of research on cancer, from the more basic discoveries dealing with both cell and molecular biology of tumour cells, to the most advanced clinical assays of conventional and new drugs. In addition, the journal has a strong commitment to facilitating the transfer of knowledge from the basic laboratory to the clinical practice, with the publication of educational series devoted to closing the gap between molecular and clinical oncologists. Molecular biology of tumours, identification of new targets for cancer therapy, and new technologies for research and treatment of cancer are the major themes covered by the educational series. Full research articles on a broad spectrum of subjects, including the molecular and cellular bases of disease, aetiology, pathophysiology, pathology, epidemiology, clinical features, and the diagnosis, prognosis and treatment of cancer, will be considered for publication.